Maple Syrup Compound a Potent Anti-Inflammatory Agent
By LabMedica International staff writers Posted on 04 Jan 2016 |
Image: Maple sap being transformed to syrup (Photo courtesy of Wikimedia Commons).
A substance that forms during the process that renders maple sap into syrup was found to have potent anti-inflammatory properties that may be developed into drugs for treatment of diseases characterized by chronic inflammation such as arthritis.
Investigators at Université Laval (Québec City, Canada) reported in the November 27, 2015, online edition of the journal Bioorganic & Medicinal Chemistry Letters that they had prepared and tested precursors of the polyphenolic compound quebecol and its derivatives. Analysis of maple sap before it was converted into syrup suggested quebecol was not naturally present in the sap but, instead, was formed during extraction or processing.
Experiments conducted with cultures of immune system macrophages demonstrated that quebecol had an anti-inflammatory effect on lipopolysaccharide (LPS)-induced NF-kappaB activation and inhibited the secretion of two pro-inflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).
Some derivatives of quebecol were even more effective than the original molecule. "The most powerful derivative has a simpler structure and is easier to synthesize than quebecol," said senior author Dr. Normand Voyer, professor of chemistry at Université Laval. "This paves the way for a whole new class of anti-inflammatory agents, inspired by quebecol, which could compensate for the low efficacy of certain treatments while reducing the risk of side effects."
Related Links:
Université Laval
Investigators at Université Laval (Québec City, Canada) reported in the November 27, 2015, online edition of the journal Bioorganic & Medicinal Chemistry Letters that they had prepared and tested precursors of the polyphenolic compound quebecol and its derivatives. Analysis of maple sap before it was converted into syrup suggested quebecol was not naturally present in the sap but, instead, was formed during extraction or processing.
Experiments conducted with cultures of immune system macrophages demonstrated that quebecol had an anti-inflammatory effect on lipopolysaccharide (LPS)-induced NF-kappaB activation and inhibited the secretion of two pro-inflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).
Some derivatives of quebecol were even more effective than the original molecule. "The most powerful derivative has a simpler structure and is easier to synthesize than quebecol," said senior author Dr. Normand Voyer, professor of chemistry at Université Laval. "This paves the way for a whole new class of anti-inflammatory agents, inspired by quebecol, which could compensate for the low efficacy of certain treatments while reducing the risk of side effects."
Related Links:
Université Laval
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples